Federal Official Gazette
No updates.
ANS news
ANS updates Reimbursement to SUS Bulletin with data through 2025
Publication compiles information on care provided in SUS and highlights the importance of monitoring in light of the aging of the population
ANS and AbbVie Farmacêutica sign agreement for access to ulcerative colitis treatment
The National Supplementary Health Agency (ANS) and the pharmaceutical company AbbVie signed a statement of responsibility for the offer of commercial discounts on the drug Risankizumab (Skyrizi), indicated for the treatment of moderate to severe ulcerative colitis. The agreement was signed in the context of the process of including the technology in the ANS List of Health Procedures and Events (Rol), whose coverage became mandatory for health plans on May 4, 2026.
The agreement provides for a minimum discount of 15% off the factory price for the 600mg version and 7% for the 180mg version of the drug, for all therapeutic indications listed in the Rol.
New regulatory axis is the subject of an article by the ANS president in the press
Portal Migalhas publishes a text by Wadih Damous that highlights the regulator’s agenda focused on the quality of health care
Open public consultations
- CP 172. Aims to receive contributions on the proposals to update the List of Health Procedures and Events (Rol). Deadline: Wednesday, May 13, 2026 to June 2, 2026.
- CP 170. Update of the regulation of the relationship between private health care plan operators and health care service providers. Deadline: Apr 1, 2026 to Jul 3, 2026.
Scheduled public hearings
- New: AP 66. Collection of contributions on the preliminary recommendation of non-incorporation for the following technologies: UAT 188 – Bimekizumab for the treatment of moderate to severe active hidradenitis suppurativa in adults who failed, were intolerant to or had a contraindication to systemic antibiotic therapy; and UAT 198 – Capivasertib for the treatment of locally advanced or metastatic breast cancer, HR+ and HER2-, with one or more alterations in PIK3CA/AKT1/PTEN. Date: May 22, 2026, from 9:30 a.m. to 12:30 p.m.
Open public calls for input
There is no open public call for input.
Open public calls
No updates.
Other news
The autism torture industry
Source: jota.info · read the full article
New remuneration models see low adoption in health care
Source: valor.globo.com · read the full article
Sources: Federal Official Gazette (DOU) and the ANS website. Press items link to the original article. This brief is for information only and does not constitute legal advice.